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Letter to the Editor
Table 1
Genotype/Allele Frequencies of the Main 11 SNPs
Nominated to Influence PD Susceptibility
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
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Genomewide Association, Parkinson Disease, and
PARK10
To the Editor:
Genomewide linkage analysis of rare familial forms of
parkinsonism has identified mutations in seven genes,
revealing a clinicopathologically and genetically hetero-
geneous syndrome.1 Less progress has been made in the
more typical late-onset form of Parkinson disease (PD
[MIM 168600]), although the recently identified LRRK2
(MIM 609007) G2019S substitution is estimated to ac-
count for ∼1% of sporadic PD cases.2 Common poly-
morphisms of familial genes may also influence suscep-
tibility to idiopathic PD.3,4 Of the 198,345 SNPs suc-
cessfully genotyped in the recent genomewide associa-
tion (GWA) study, 26 had notably different allele fre-
quencies between patients and controls in both tiers
( ).5 Fifteen of these SNPs had opposite directionsP ! .01
of effect (disease risk or protection) in tiers 1 and 2. The
remaining 11 SNPs were proposed as markers for new
genes/chromosomal loci that influence susceptibility to
PD. In addition, two SNPs in tier 2 (rs682705 and
rs7520966) were highlighted in the PARK10 locus
(MIM 606852), which nominated the gene LOC200008
in disease susceptibility.
The PARK10 locus on chromosome 1p32 was origi-
nally identified in a genomewide linkage analysis of 117
patients from 51 Icelandic families (maximum Z plr
at D1S231, with a LOD-1, 7.6-cM support interval4.8
from D1S2874 to D1S475).6 Iceland has a well-char-
acterized genealogy that is powerful for family-based
linkage studies. The ancestral founders of Iceland have
Scandinavian patrilineal inheritance with a minor Celtic
matrilineal component.7 Assuming that the PARK10
mutation predates the Icelandic settlement, we reasoned
that the 1p32 susceptibility gene might be more readily
found in patients with PD originating from Scandinavian
or Celtic populations. In parallel to the study of Mar-
aganore et al.,5 we have been mapping the PARK10 lo-
cus. Genotypes from 28 SNPs (including rs682705 and
rs7520966) within a 132-kb region of chromosome
1p32 located around the LOC200008 gene have been
analyzed in two well-characterized case-control series
from Norway and Ireland. In addition, we attempted to
replicate findings for the two PARK10 SNPs in a U.S.
series collected at the Mayo Clinic in Jacksonville, FL.
We then employed all three case-control series to inves-
tigate the genotype/allele frequencies of the main 11
SNPs nominated to influence PD susceptibility.5 Power
was comparable to the original study (180% at ap
for odds ratios [ORs] 12.0 and for disease-allele0.05
frequencies 10.035), and genotyping call rates were
195% for all markers (table 1).
In total, Norwegian samples included 676 subjects
(cases and controls) with a mean age (SD) of 70 11
years, Irish samples included 372 subjects with a mean
age (SD) of 61  13 years, and the U.S. samples in-
cluded 522 subjects with a mean age (SD) of 71 10
years. All patients were examined and were observed lon-
gitudinally by a movement-disorders neurologist (J.O.A.,
J.M.G., D.G., T.L., Z.K.W., and R.J.U.), and they were
given a diagnosis of PD in accordance with published
criteria.8 Each patient was individually matched, on the
basis of age (4 years) and ethnicity, to an unrelated
control without evidence of neurological disease. The
ethical review boards at each institution involved ap-
proved the study, and all participants provided informed
consent.
SNP genotyping was performed using TaqMan chem-
istry on an ABI7900 genetic analyzer; in cases where
genotype data was available for only one subject of a
matched pair, the other subject was retained in the anal-
ysis. For the controls in each population, x2 tests of
Hardy-Weinberg equilibrium (HWE) were implemented
using Haploview.9 Optimal SNP coverage for association
analysis of the LOC200008 gene was determined em-
pirically by the construction of linkage-disequilibrium
(LD) maps in Norwegian and Irish samples, onto which
haplotype blocks were assigned (fig. 1).10,11 ORs for dis-
ease association, with corresponding 95% CIs, were sub-
sequently calculated using logistic-regression models ad-
justed for age and sex. Overall ORs combining data from
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Figure 1 Metric LD map and haplotype block structure of the investigated region. A, LD map providing information about LD patterns
in the investigated candidate region, through locations expressed in LDUs. LDUs have an inverse relationship with LD, with regions of extensive
recombination having many LDUs. The physical position of the gene in the region LOC200008 is marked with an arrow. All 28 SNPs genotyped
are reported, although the symbols () may be obscured for SNPs that lie in close physical proximity and high LD. SNPs rs682705 and
rs7520966 are denoted by an asterisk (*). B, LD structure of the candidate region. Black and dark gray cells, strong LD; gray cells, intermediate;
and light gray and white cells, evidence for historical recombination. The haplotype block structure of the region is defined according to Gabriel
et al.10 An asterisk denotes SNPs rs682705 and rs7520966. The LD map and haplotype structure were constructed using genotypes from the
Norwegian sample. Similar results were obtained for the Irish population.
all three sites were additionally adjusted for site. Pre-
vious studies have nominated the PARK10 locus as an
age-at-onset modifier in PD12; thus, we also assessed the
influence of 1p32 SNPs variability on this disease trait,
using linear-regression models adjusted for sex.
There was no evidence of association with PD for any
of the 28 genotyped 1p32 SNPs in our study (all SNP
after applying Bonferroni correction in bothP 1 .05
population samples). Haplotype frequencies between pa-
tients and controls were not significantly different for
the haplotype blocks identified; nor was the age at on-
set in patients associated with any single marker or
haplotype (all corrected ). Of note, the ancestralP 1 .05
recombination and haplotype blocks apparent within
Norwegian and Irish samples were comparable for this
interval at this marker resolution. The average number
of SNPs per LD unit (LDU) was 6.8 (mean LDU between
markers 0.15, range 0–0.63), indicating that the number
of SNPs genotyped within and flanking LOC200008
should be sufficient for examination of the region.11 In
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Table 2
11 SNPs Nominated in GWA Study as Genetic Susceptibility Loci for PD
dbSNP
ACCESSION
NUMBER CHROMOSOME
POSITION
(bp)
THIS STUDY MARAGANORE ET AL.5
Control MAF
Estimated OR
(95% CI)a
Combined
P
(np 1,570)
Control MAF P
Estimated OR
(95% CI)b
Combined P
( )np 1,550Ireland Norway United States Tier 1 Tier 2 Tier 1 Tier 2
rs7702187 5p15.2 9385281 .17 .18 .18 .88 (.74–1.06) .18 .18 .20 .001 .002 1.74 (1.36–2.24) 7.62 # 106
rs10200894 2q36 228642637 .13 .11 .09 .96 (.77–1.21) .74 .12 .13 .009 .001 1.84 (1.38–2.45) 1.70 # 105
rs2313982 4q31.1 139145665 .05 .11 .09 .93 (.73–1.18) .54 .07 .06 .006 .002 2.01 (1.44–2.79) 1.79 # 105
rs17329669 7p14 36625169 .13 .12 .14 1.01 (.82–1.24) .92 .13 .11 .008 .001 1.71 (1.33–2.21) 2.30 # 105
rs7723605 5p15.3 5407615 .13 .14 .13 .91 (.75–1.12) .38 .12 .09 .010 .002 1.78 (1.35–2.35) 3.30 # 105
ss46548856 10q21 58986929 .09 .08 .11 .93 (.73–1.19) .58 .09 .11 .003 .002 1.88 (1.38–2.57) 3.65 # 105
rs16851009 2q24 166456214 .11 .11 .12 .95 (.76–1.18) .63 .09 .08 .002 .009 1.84 (1.36–2.49) 4.17 # 105
rs2245218 1p36.2 13885132 .19 .17 .15 .95 (.79–1.14) .57 .11 .13 .002 .002 1.67 (1.29–2.14) 4.61 # 105
rs7878232 Xq28 150516943 .25 .23 .25 1.10 (.97–1.25) .15 .29 .26 .003 .010 1.38 (1.17–1.62) 6.87 # 105
rs1509269 4q31.1 139111329 .08 .13 .13 .94 (.76–1.17) .58 .10 .09 .005 .008 1.71 (1.30–2.26) 9.21 # 105
rs11737074 4q27 125438978 .21 .20 .21 1.05 (.89–1.25) .55 .19 .19 .007 .005 1.50 (1.21–1.86) 1.55 # 104
NOTE.—In this study, MAFs are not significantly different between the populations. No P values are corrected for multiple testing. SNPs are ordered by combined P value, per Maraganore
et al.5
a The direction of effect of the estimated OR observed in this study for each SNP is shown (i.e., 11 risk and !1 protective).
b Estimated ORs in the study by Maraganore et al.5 do not indicate the direction of effect relative to the MAF.
addition, the two PARK10 SNPs showed no significant
association within the U.S. series ( ). None of theP 1 .05
other 11 SNPs nominated by the GWA study had different
allele frequencies or genotype distributions between af-
fected subjects and matched controls (all SNP inP 1 .05
all populations independently or as a combined sample
set) (table 2). There was no evidence of departure from
HWE in controls ( in all population controls).P 1 .01
Our study indicates that genetic variability within the
LOC200008 gene is unlikely to explain the PARK10
susceptibility locus for PD. Sadly, the lack of disease
association and replication in an independent U.S. series
of comparable power suggests that the original findings
may be spurious. Failure to nominate LOC200008 as
the PARK10 gene in our population samples provides
empirical support for statistical caveats concerning GWA
studies. Implicit in multiple testing is false discovery,
even in well-designed studies, and there are several po-
tential sources of bias.13 Of note, neither PARK10 SNP
rs682705 nor rs7520966 fulfilled the main criterion for
being genotyped in tier 2 ( in tier 1 overall anal-P ! .01
ysis), but each was included with a less stringent associ-
ation criterion ( in tier 1 overall analysis) becauseP ! .05
of its physical position within a PARK locus. Interestingly,
the combined P value for rs682705 ( )6Pp 9.07# 10
is the second-lowest P value of the overall study, even
though it did not fulfill the inclusion criteria. Individual-
level data from the GWA study is not yet available, but,
in our study, these two SNPs also appear to be in LD
(pairwise ), as suggested by Maraganore et al.5;2r 1 0.9
in addition, the minor-allele frequencies (MAFs) of the
two SNPs are comparable across studies and popula-
tions. The former suggests less-than-optimal haplotype
tagging in the initial study, whereas the latter argues
against technical errors in genotyping, but neither pro-
vides sufficient explanation for the positive findings ob-
served elsewhere.5
We found no evidence of direct association between
the 11 SNPs nominated in the GWA study and disease
in the three independent populations or in a combined
sample group ( ) (table 2). However, for thesenp 1,570
loci, we did not employ a gene-based approach (nor did
we fine-map each region as with PARK10), as advocated
elsewhere14; we await the results of further replication
studies. Of note, in the study by Maraganore et al.,5 the
rs7702187 SNP within SEMA5A (MIM 609297) had
the lowest combined P value ( ); how-6Pp 7.62# 10
ever, a total of 53 SNPs were examined in this gene in
tier 1. Only rs7702187 was significant before correction
( ), which supports the possibly spurious naturePp .001
of this and the other associations. The MAFs observed
in our three populations and in that of the GWA study
are comparable, which argues against population bias/
heterogeneity (table 2).
The number of SNPs highlighted in each tier of the
original study is consistent with chance—that is, 1% of
SNPs use a significance level of . None of the PP ! .01
values obtained by Maraganore et al.5 meets a Bonfer-
roni correction for multiple testing, although this stan-
dard may be too conservative in GWA, since it fails to
account for LD and incorrectly assumes that chromo-
somal markers are independent. A consensus on the most
appropriate correction for multiple testing has yet to be
reached. Now that genomewide data sets have been gen-
erated, there exists the possibility to use these to develop
appropriate statistical methods to identify true positive
results.15
In the interim, we recommend that enthusiasm for
positive findings should be tempered by the strength of
the evidence, the population-attributable risk, and the
differences in SNP allele/genotype frequencies between
cases and controls. If allele frequencies are significantly
different, genomic controls might be used to assess pop-
ulation substructure. It is important that future studies
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employ multiple independent sample series, each with
sufficient power to verify significant genetic associations,
before publication.16 However, lack of evidence for an
association is not the same as evidence against one; thus,
lack of replication should also be interpreted with
caution.
Over the few next years, the number of GWA studies
will increase, and it is important to learn from the ex-
periences gained by the few studies performed to date.
Although our negative findings suggest that the conclu-
sions drawn from the study by Maraganore et al.5 might
be based on spurious associations, further analysis of
individual-level raw data is now necessary. The recent
identification of a complement factor H polymorphism
in age-related macular degeneration in a GWA study and
the identical findings by two other groups using other
study designs demonstrates that this approach can be
used successfully.17–19 It may be that, because of the het-
erogeneous nature of PD, associations with a gestalt phe-
notype are masked by background variation in SNP in-
formativeness, population strata, and insufficient power.
It is, therefore, crucial that future associations are val-
idated and that analysis is performed to resolve the un-
derlying cause of association in the sample population.
GWA studies may still provide direction for the genetic
analysis of heterogenous complex traits, but, in the short
term, they may exacerbate the problem of replication
failure in association studies.
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